Turning Point Therapeutics (TPTX) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access TPTX Annual Balance Sheets →
Examining balance sheet movements between Turning Point Therapeutics and Jun 30 2021 reveals how Jun 30 2022 adjusts its asset composition and liability profile.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2022)
(Mar 31 2022) (Dec 31 2021) (Sep 30 2021) (Jun 30 2021)
Assets
Cash & cash equivalent290.15
Marketable Securities, Current SH528.14
Cash & Short-term Investments818.00
Other Current Assets0.00
Prepaid Expense And Other Assets Current13.38
Total Current Assets831.67
Equipment/Property/Plant Net5.05
Other Assets, Noncurrent6.62
Total Assets843.34
Liabilities
Accounts Payable, Current AC7.93
Employee-related Liabilities, Current AC11.87
Total Current Liabilities49.42
Total Long-term Debt0.00
Other liabilities, Noncurrent0.00
Accrued Expenses And Other Current Liabilities25.57
Operating Lease Liability Current4.05
Operating Lease Liability Noncurrent0.89
Total Liabilities50.31
Stockholders' Equity
Common Stock Value0.01
Additional Paid In Capital Common Stock1,514.19
Retained Earnings / Accumulated Deficit-714.26
Other Equity-6.91
Common Stockholder's Equity793.02
Total Stockholder's Equity793.02
Liabilities & Stockholder's Equity843.34
4 historic quarters locked

Sign in to unlock the full Turning Point Therapeutics balance sheet history.

About Turning Point Therapeutics Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0000950170-22-015542

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.